G-Treebnt Co., Ltd.

College of Medicine Pochon Cha University Industry-Academic Cooperation Foundation

Regentree, LLC

Chameditech Co., Ltd.

Sin Wook Kang

Kyoungsun Kim

Ji Hye Sung

Si Young Lee

Jin Sung Kim

Jeongbeob Seo

Hye Sun Jeon

Tae Heum Um

Kwang Hyuong Lee

Yong Su Kwon

Won Suk Yang

Tae Jong Yoon

Chae Woon Lee

Kwang Hoe Chung

Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T&#x3b2;4), T&#x3b2;4 fragments, T&#x3b2;4 isoforms, T&#x3b2;4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.

Methods of treating dry eye syndrome

The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin &#x3b2;4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin &#x3b2;4 is carried out in the presence of an inert gas, thus the contact of thymosin &#x3b2;4 with oxygen is blocked and the oxidation of thymosin &#x3b2;4 can be prevented and the pharmacological activity of thymosin &#x3b2;4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin &#x3b2;4 in a stable state for a long time.

Method for preparing ophthalmic preparation containing thymosin beta-4

The present invention relates to a novel organic compound, a near-infrared fluorescent constant medium containing the same, and a method for nano-granulating the constant medium.

Organic compound, near-infrared fluorescent constant medium containing same, and method for nano-granulating constant medium

The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Composition containing thymosin beta 4, and pharmaceutical formulation comprising same

The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin &#x3b2;4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin &#x3b2;4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.

Pharmaceutical composition for treating or preventing corneal wound comprising thymosin &#x3b2;4 and citric acid

Growing community of inventors

Gyeonggi-do, South Korea

Sin Wook Kang